• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

最佳药物组合与最小命中集

Optimal drug combinations and minimal hitting sets.

作者信息

Vazquez Alexei

机构信息

The Simons Center for Systems Biology, Institute for Advanced Study, Einstein Drive, Princeton, New Jersey 08540, USA.

出版信息

BMC Syst Biol. 2009 Aug 6;3:81. doi: 10.1186/1752-0509-3-81.

DOI:10.1186/1752-0509-3-81
PMID:19660129
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2738654/
Abstract

BACKGROUND

Identifying effective drug combinations that significantly improve over single agents is a challenging problem. Pairwise combinations already represent a huge screening effort. Beyond two drug combinations the task seems unfeasible.

RESULTS

In this work we introduce a method to uncover drug combinations with a putative effective response when presented to a heterogeneous population of malignant agents (strains), such as cancer cell lines or viruses. Using data quantifying the effect of single drugs over several individual strains, we search for minimal drug combinations that successfully target all strains. We show that the latter problem can be mapped to a minimal hitting set problem in mathematics. We illustrate this approach using data for the NCI60 panel of tumor derived cell lines, uncovering 14 anticancer drug combinations.

CONCLUSION

The drug-response graph and the associated minimal hitting set method can be used to uncover effective drug combinations in anticancer drug screens and drug development programs targeting heterogeneous populations of infectious agents such as HIV.

摘要

背景

识别出比单一药物显著更有效的药物组合是一个具有挑战性的问题。成对组合已经代表了巨大的筛选工作量。超过两种药物的组合,这项任务似乎不可行。

结果

在这项工作中,我们介绍了一种方法,当将其应用于异质性的恶性病原体群体(菌株),如癌细胞系或病毒时,可发现具有假定有效反应的药物组合。利用量化单一药物对多个个体菌株作用的数据,我们寻找能成功靶向所有菌株的最小药物组合。我们表明,后一个问题可以映射到数学中的最小命中集问题。我们使用来自肿瘤衍生细胞系的NCI60面板的数据来说明这种方法,发现了14种抗癌药物组合。

结论

药物反应图和相关的最小命中集方法可用于在抗癌药物筛选以及针对诸如HIV等异质性感染原群体的药物开发项目中发现有效的药物组合。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b74b/2738654/ee43dc7c2ebd/1752-0509-3-81-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b74b/2738654/048f552b9713/1752-0509-3-81-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b74b/2738654/9afe5a4e32cd/1752-0509-3-81-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b74b/2738654/ee43dc7c2ebd/1752-0509-3-81-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b74b/2738654/048f552b9713/1752-0509-3-81-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b74b/2738654/9afe5a4e32cd/1752-0509-3-81-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b74b/2738654/ee43dc7c2ebd/1752-0509-3-81-3.jpg

相似文献

1
Optimal drug combinations and minimal hitting sets.最佳药物组合与最小命中集
BMC Syst Biol. 2009 Aug 6;3:81. doi: 10.1186/1752-0509-3-81.
2
Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations.大规模泛癌种细胞系筛查鉴定出潜在可用药和有效药物组合。
Cancer Discov. 2024 May 1;14(5):846-865. doi: 10.1158/2159-8290.CD-23-0388.
3
A pan-cancer screen identifies drug combination benefit in cancer cell lines at the individual and population level.泛癌种筛选在个体和群体水平上鉴定了癌症细胞系中的药物组合获益。
Cell Rep Med. 2024 Aug 20;5(8):101687. doi: 10.1016/j.xcrm.2024.101687.
4
Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors.实体瘤中靶向药物与化疗有效及拮抗联合用药的生物学见解。
Cancer Metastasis Rev. 2014 Mar;33(1):295-307. doi: 10.1007/s10555-013-9451-7.
5
Implementation of the NCI-60 Human Tumor Cell Line Panel to Screen 2260 Cancer Drug Combinations to Generate >3 Million Data Points Used to Populate a Large Matrix of Anti-Neoplastic Agent Combinations (ALMANAC) Database.实施 NCI-60 人肿瘤细胞系面板筛选 2260 种癌症药物组合,生成超过 300 万个数据点,用于填充大型抗肿瘤药物组合(ALMANAC)数据库矩阵。
SLAS Discov. 2019 Mar;24(3):242-263. doi: 10.1177/2472555218812429. Epub 2018 Nov 30.
6
A kernelisation approach for multiple d-Hitting Set and its application in optimal multi-drug therapeutic combinations.一种多 d-击中集的核化方法及其在最优多药物治疗组合中的应用。
PLoS One. 2010 Oct 18;5(10):e13055. doi: 10.1371/journal.pone.0013055.
7
Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines.分析美国国立癌症研究所(NCI)60 人肿瘤细胞系panel 中食品和药物管理局批准的抗癌药物。
Mol Cancer Ther. 2010 May;9(5):1451-60. doi: 10.1158/1535-7163.MCT-10-0106. Epub 2010 May 4.
8
A microfluidics platform for combinatorial drug screening on cancer biopsies.一种用于癌症活检的组合药物筛选的微流控平台。
Nat Commun. 2018 Jun 22;9(1):2434. doi: 10.1038/s41467-018-04919-w.
9
Modernizing the NCI60 Cell Line Screen for Phenotypic Drug Discovery in the 21st Century.在 21 世纪实现 NCI60 细胞系筛选的现代化,以进行表型药物发现。
Cancer Res. 2024 Aug 1;84(15):2397-2399. doi: 10.1158/0008-5472.CAN-24-1506.
10
Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer.靶向生长因子受体、CDKs 和下游信号分子的药物在一系列胰腺癌细胞系中的协同作用及拮抗组合的鉴定:对胰腺癌未来临床试验的启示。
Oncol Rep. 2020 Dec;44(6):2581-2594. doi: 10.3892/or.2020.7822. Epub 2020 Oct 22.

引用本文的文献

1
The landscape of receptor-mediated precision cancer combination therapy via a single-cell perspective.从单细胞角度看受体介导的精准癌症联合治疗的前景。
Nat Commun. 2022 Mar 25;13(1):1613. doi: 10.1038/s41467-022-29154-2.
2
Network medicine in Cardiovascular Research.网络医学在心血管研究中的应用。
Cardiovasc Res. 2021 Aug 29;117(10):2186-2202. doi: 10.1093/cvr/cvaa321.
3
Network Pharmacology-Guided Development of a Novel Integrative Regimen to Prevent Acute Graft-vs.-Host Disease.基于网络药理学指导开发预防急性移植物抗宿主病的新型综合方案

本文引用的文献

1
Models from experiments: combinatorial drug perturbations of cancer cells.实验模型:癌细胞的组合药物扰动
Mol Syst Biol. 2008;4:216. doi: 10.1038/msb.2008.53. Epub 2008 Sep 2.
2
Drug target identification using side-effect similarity.利用副作用相似性进行药物靶点识别。
Science. 2008 Jul 11;321(5886):263-6. doi: 10.1126/science.1158140.
3
mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia.雷帕霉素靶蛋白抑制剂与甲氨蝶呤具有协同作用:一种治疗急性淋巴细胞白血病的有效联合疗法。
Front Pharmacol. 2018 Dec 13;9:1440. doi: 10.3389/fphar.2018.01440. eCollection 2018.
4
GDA, a web-based tool for Genomics and Drugs integrated analysis.GDA,一个用于基因组学和药物综合分析的网络工具。
Nucleic Acids Res. 2018 Jul 2;46(W1):W148-W156. doi: 10.1093/nar/gky434.
5
Critical controllability analysis of directed biological networks using efficient graph reduction.利用有效的图约简对有向生物网络进行关键可控性分析。
Sci Rep. 2017 Oct 30;7(1):14361. doi: 10.1038/s41598-017-14334-8.
6
Critical controllability in proteome-wide protein interaction network integrating transcriptome.整合转录组的蛋白质组范围蛋白质相互作用网络中的关键可控性
Sci Rep. 2016 Apr 4;6:23541. doi: 10.1038/srep23541.
7
Determining Associations between Human Diseases and non-coding RNAs with Critical Roles in Network Control.确定人类疾病与在网络控制中起关键作用的非编码RNA之间的关联。
Sci Rep. 2015 Oct 13;5:14577. doi: 10.1038/srep14577.
8
Analysis of the robustness of network-based disease-gene prioritization methods reveals redundancy in the human interactome and functional diversity of disease-genes.基于网络的疾病基因优先级排序方法的稳健性分析揭示了人类相互作用组中的冗余性以及疾病基因的功能多样性。
PLoS One. 2014 Apr 14;9(4):e94686. doi: 10.1371/journal.pone.0094686. eCollection 2014.
9
Combinatorial therapy discovery using mixed integer linear programming.组合疗法发现使用混合整数线性规划。
Bioinformatics. 2014 May 15;30(10):1456-63. doi: 10.1093/bioinformatics/btu046. Epub 2014 Jan 24.
10
Optimization of personalized therapies for anticancer treatment.抗癌治疗个性化疗法的优化。
BMC Syst Biol. 2013 Apr 12;7:31. doi: 10.1186/1752-0509-7-31.
Blood. 2008 Sep 1;112(5):2020-3. doi: 10.1182/blood-2008-02-137141. Epub 2008 Jun 10.
4
Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm.使用随机搜索算法引导的组合药物对细胞功能进行闭环控制。
Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5105-10. doi: 10.1073/pnas.0800823105. Epub 2008 Mar 20.
5
Statistical mechanics of the hitting set problem.击中集问题的统计力学
Phys Rev E Stat Nonlin Soft Matter Phys. 2007 Oct;76(4 Pt 1):041124. doi: 10.1103/PhysRevE.76.041124. Epub 2007 Oct 18.
6
Drug-target network.药物-靶点网络
Nat Biotechnol. 2007 Oct;25(10):1119-26. doi: 10.1038/nbt1338.
7
The NCI60 human tumour cell line anticancer drug screen.美国国立癌症研究所60种人类肿瘤细胞系抗癌药物筛选
Nat Rev Cancer. 2006 Oct;6(10):813-23. doi: 10.1038/nrc1951.
8
Systematic discovery of multicomponent therapeutics.多组分疗法的系统性发现。
Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7977-82. doi: 10.1073/pnas.1337088100. Epub 2003 Jun 10.